NDA 215888 · Mycovia Pharms
Vivjoa
Oteseconazole · Oral · Azole Antifungal
NovelPriority reviewCDER novel approval, Apr 26, 2022: To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
Last checked: Nov 20, 2026Latest source record: Apr 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Apr 26, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
4 Phase 3, 1 recruiting
FAERS reports
43
3 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2026.
VIVJOA™ is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. ( 1 ) 1.1 Vulvovaginal Candidiasis VIVJOA is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential [see Warnings and Precautions (5.1) , Use in Specific Populations (8.3) , and Clinical Studies (14) ] . 1.2 Usage If specimens for fungal culture are obtained prior to therapy, antifungal therapy may be instituted before the results of the cultures are known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Mechanism: Oteseconazole is an antifungal drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 26, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- VIVJOA · OTESECONAZOLE 150MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oteseconazole" as an intervention, any sponsor and status, largest first.
- Platform Trial For Cryptococcal Meningitis (PLATFORM-CM)Pivotal-lookingRecruiting
David BoulwareAcademic, hospital or other
NCT06666322 · 2,000 participants (planned) · Start May 28, 2025 · Primary completion Apr 21, 2032
Drug: Standard of care; Oteseconazole - antifungal therapy 1 and 3 more · For: Hiv; Cryptococcal Meningitis
Sites: Kampala, Uganda; Mbarara, Uganda
- A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)Pivotal-lookingCompleted
Mycovia Pharmaceuticals Inc.Industry
NCT03562156 · 438 participants · Start Aug 16, 2018 · Primary completion Oct 19, 2020
Drug: Oteseconazole (VT-1161); Placebo · For: Recurrent Vulvovaginal Candidiasis
Sites: Birmingham, Alabama; San Diego, California; Lauderdale Lakes, Florida · 25 sites in all
- A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)Pivotal-lookingCompleted
Mycovia Pharmaceuticals Inc.Industry
NCT03561701 · 425 participants · Start Aug 23, 2018 · Primary completion Oct 13, 2020
Drug: Oteseconazole (VT-1161); Placebo · For: Recurrent Vulvovaginal Candidiasis
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 14 sites in all
- Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast InfectionsPivotal-lookingCompleted
Mycovia Pharmaceuticals Inc.Industry
NCT03840616 · 219 participants · Start Mar 13, 2019 · Primary completion Dec 2, 2020
Drug: Oteseconazole (VT-1161) 150mg capsule; Fluconazole 150mg capsule and 1 more · For: Recurrent Vulvovaginal Candidiasis
Sites: Tucson, Arizona; Encino, California; Los Angeles, California · 33 sites in all
- Platform Trial for Salvage Consolidation Therapy in Dimorphic FungiNot yet recruiting
University of MinnesotaAcademic, hospital or other
NCT07804368 · 30 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2028
Drug: Oteseconazole · For: Coccidioidomycosis; Blastomycosis; Histoplasmosis and 2 more
Sites: Phoenix, Arizona; Tempe, Arizona; Davis, California · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective8
- fungal infection5
- dysuria4
- inappropriate schedule of product administration4
- off label use4
- vulvovaginal pruritus4
- dizziness3
- nausea3
- candida infection2
- diarrhoea2
- erythema2
- headache2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 14 |
| 2024 | 9 |
| 2025 | 4 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vivjoa (Oteseconazole)
2024 spending
$323K
Beneficiaries
101
114 claims
Per beneficiary
$3,203
$159.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $95,338 |
| 2023 | $222,182 |
| 2024 | $323,472 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Wang X, Chen L, Ruan H, et al. · Antimicrob Agents Chemother 2024 · Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.
Sobel JD, Donders G, Degenhardt T, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, et al. · Am J Obstet Gynecol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Evaluation of vaginitis and its treatment.
McKinney SA, Gross EA · Curr Opin Obstet Gynecol 2026 · Systematic Review
- A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis.
Brand SR, Sobel JD, Nyirjesy P, et al. · Clin Infect Dis 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Oteseconazole versus fluconazole in the treatment of acute candidiasis: a systematic review and meta-analysis.
de Farias EH, Pereira AGA, da Silva AMP, et al. · Rev Bras Ginecol Obstet 2026 · Systematic Review, Meta-Analysis
Sponsor: Mycovia Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.